EGFR and neoplasm: However, tumor progression often occurs via the emergence of the EGFR T790 M resistance mutation during the treatment of EGFR-mutant lung adenocarcinomas patients with first-generation EGFR tyrosine kinase inhibitors (TKIs; Erlotinib, Gefitinib) [10, 11].